LEAH BARJENBRUCH: Open Payments
NPI 1295193217 · GRAND JUNCTION, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,499 in 69 payments from 16 companies in 2025. Trend: 2023 $886 · 2024 $1,670 · 2025 $1,499
Food & beverage: $1,499
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $357 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $204 |
| Gilead Sciences, Inc. | 9 | $193 |
| Ipsen Biopharmaceuticals, Inc | 7 | $151 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $104 |
| Madrigal Pharmaceuticals | 4 | $88 |
| Ardelyx, Inc. | 3 | $83 |
| Janssen Biotech, Inc. | 3 | $76 |
| Lilly USA, LLC | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
Products named: RINVOQ, ENTYVIO, IQIRVO, XIFAXAN, REZDIFFRA, IBSRELA, DUPIXENT, TREMFYA.
Industry payments across CO — which companies pay providers there.
